vs
CoStar Group（CSGP）与爱德华生命科学（EW）财务数据对比。点击上方公司名可切换其他公司
爱德华生命科学的季度营收约是CoStar Group的1.8倍（$1.6B vs $899.9M），爱德华生命科学净利率更高（23.1% vs 5.2%，领先17.9%），CoStar Group同比增速更快（26.9% vs 16.7%），过去两年CoStar Group的营收复合增速更高（17.1% vs 9.7%）
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
CSGP vs EW — 直观对比
营收规模更大
EW
是对方的1.8倍
$899.9M
营收增速更快
CSGP
高出10.2%
16.7%
净利率更高
EW
高出17.9%
5.2%
两年增速更快
CSGP
近两年复合增速
9.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $899.9M | $1.6B |
| 净利润 | $46.5M | $380.7M |
| 毛利率 | 78.6% | 78.0% |
| 营业利润率 | 5.5% | 1.8% |
| 净利率 | 5.2% | 23.1% |
| 营收同比 | 26.9% | 16.7% |
| 净利润同比 | -22.2% | 6.8% |
| 每股收益（稀释后） | $0.12 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGPEW
| Q1 26 | — | $1.6B | ||
| Q4 25 | $899.9M | $1.6B | ||
| Q3 25 | $833.6M | $1.6B | ||
| Q2 25 | $781.3M | $1.5B | ||
| Q1 25 | $732.2M | $1.4B | ||
| Q4 24 | $709.4M | $1.4B | ||
| Q3 24 | $692.6M | $1.4B | ||
| Q2 24 | $677.8M | $1.4B |
净利润CSGPEW
| Q1 26 | — | $380.7M | ||
| Q4 25 | $46.5M | $91.2M | ||
| Q3 25 | $-30.9M | $291.1M | ||
| Q2 25 | $6.2M | $333.2M | ||
| Q1 25 | $-14.8M | $358.0M | ||
| Q4 24 | $59.8M | $385.6M | ||
| Q3 24 | $53.0M | $3.1B | ||
| Q2 24 | $19.2M | $366.3M |
毛利率CSGPEW
| Q1 26 | — | 78.0% | ||
| Q4 25 | 78.6% | 78.1% | ||
| Q3 25 | 79.3% | 77.8% | ||
| Q2 25 | 78.5% | 77.5% | ||
| Q1 25 | 79.1% | 78.7% | ||
| Q4 24 | 80.1% | 78.9% | ||
| Q3 24 | 79.7% | 80.6% | ||
| Q2 24 | 80.0% | 79.9% |
营业利润率CSGPEW
| Q1 26 | — | 1.8% | ||
| Q4 25 | 5.5% | 9.6% | ||
| Q3 25 | -6.1% | 19.8% | ||
| Q2 25 | -3.5% | 26.8% | ||
| Q1 25 | -5.8% | 27.9% | ||
| Q4 24 | 5.6% | 22.6% | ||
| Q3 24 | 3.4% | 25.9% | ||
| Q2 24 | -2.4% | 26.8% |
净利率CSGPEW
| Q1 26 | — | 23.1% | ||
| Q4 25 | 5.2% | 5.8% | ||
| Q3 25 | -3.7% | 18.7% | ||
| Q2 25 | 0.8% | 21.7% | ||
| Q1 25 | -2.0% | 25.3% | ||
| Q4 24 | 8.4% | 27.8% | ||
| Q3 24 | 7.7% | 226.7% | ||
| Q2 24 | 2.8% | 26.7% |
每股收益（稀释后）CSGPEW
| Q1 26 | — | $0.66 | ||
| Q4 25 | $0.12 | $0.16 | ||
| Q3 25 | $-0.07 | $0.50 | ||
| Q2 25 | $0.01 | $0.56 | ||
| Q1 25 | $-0.04 | $0.61 | ||
| Q4 24 | $0.14 | $0.65 | ||
| Q3 24 | $0.13 | $5.13 | ||
| Q2 24 | $0.05 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | — |
| 总债务越低越好 | $140.0M | — |
| 股东权益账面价值 | $8.3B | — |
| 总资产 | $10.5B | — |
| 负债/权益比越低杠杆越低 | 0.02× | — |
8季度趋势，按日历期对齐
现金及短期投资CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | $4.2B | ||
| Q3 25 | $1.9B | $3.8B | ||
| Q2 25 | $3.6B | $4.1B | ||
| Q1 25 | $3.7B | $3.9B | ||
| Q4 24 | $4.7B | $4.0B | ||
| Q3 24 | — | $4.4B | ||
| Q2 24 | — | $2.0B |
总债务CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | $140.0M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — |
股东权益CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | $8.3B | $10.3B | ||
| Q3 25 | $8.6B | $10.2B | ||
| Q2 25 | $8.6B | $10.5B | ||
| Q1 25 | $8.6B | $10.1B | ||
| Q4 24 | $7.6B | $10.0B | ||
| Q3 24 | $7.5B | $9.5B | ||
| Q2 24 | $7.4B | $7.4B |
总资产CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | $10.5B | $13.7B | ||
| Q3 25 | $10.8B | $13.3B | ||
| Q2 25 | $10.5B | $13.5B | ||
| Q1 25 | $10.4B | $13.0B | ||
| Q4 24 | $9.3B | $13.1B | ||
| Q3 24 | $9.1B | $13.0B | ||
| Q2 24 | $9.1B | $10.1B |
负债/权益比CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | — |
| 自由现金流经营现金流 - 资本支出 | $101.3M | — |
| 自由现金流率自由现金流/营收 | 11.3% | — |
| 资本支出强度资本支出/营收 | 6.8% | — |
| 现金转化率经营现金流/净利润 | 3.49× | — |
| 过去12个月自由现金流最近4个季度 | $123.0M | — |
8季度趋势，按日历期对齐
经营现金流CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | $162.1M | $450.9M | ||
| Q3 25 | $68.2M | $573.7M | ||
| Q2 25 | $146.5M | $290.2M | ||
| Q1 25 | $53.2M | $280.4M | ||
| Q4 24 | $94.6M | $-127.5M | ||
| Q3 24 | $100.3M | $351.8M | ||
| Q2 24 | $58.1M | $371.5M |
自由现金流CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | $101.3M | $353.5M | ||
| Q3 25 | $-5.5M | $516.2M | ||
| Q2 25 | $27.7M | $240.9M | ||
| Q1 25 | $-500.0K | $224.4M | ||
| Q4 24 | $25.2M | $-177.3M | ||
| Q3 24 | $40.2M | $299.9M | ||
| Q2 24 | $-14.7M | $286.1M |
自由现金流率CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | 11.3% | 22.5% | ||
| Q3 25 | -0.7% | 33.2% | ||
| Q2 25 | 3.5% | 15.7% | ||
| Q1 25 | -0.1% | 15.9% | ||
| Q4 24 | 3.6% | -12.8% | ||
| Q3 24 | 5.8% | 22.1% | ||
| Q2 24 | -2.2% | 20.9% |
资本支出强度CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 6.2% | ||
| Q3 25 | 8.8% | 3.7% | ||
| Q2 25 | 15.2% | 3.2% | ||
| Q1 25 | 7.3% | 4.0% | ||
| Q4 24 | 9.8% | 3.6% | ||
| Q3 24 | 8.7% | 3.8% | ||
| Q2 24 | 10.7% | 6.2% |
现金转化率CSGPEW
| Q1 26 | — | — | ||
| Q4 25 | 3.49× | 4.94× | ||
| Q3 25 | — | 1.97× | ||
| Q2 25 | 23.63× | 0.87× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 1.58× | -0.33× | ||
| Q3 24 | 1.89× | 0.11× | ||
| Q2 24 | 3.03× | 1.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
EW
暂无分部数据
